E
THRIVE™ · EVALUATION

You deployed it. Are you actually checking?

Clinical AI is only as trustworthy as the evidence that it continues to perform as intended. Evaluation readiness spans the capacity to formally commission, continuously monitor, detect drift, manage incidents, and decommission when warranted.

Assess your readiness
ACCURACYDRIFTPERFORMANCE OVER TIME

Most healthcare organisations treat AI deployment as the finish line. The reality: deployment is where the risk begins. Models drift. Data distributions shift. Clinical workflows evolve around the AI in unintended ways. Without structured evaluation capability, organisations have no way to know whether their AI is still performing — or whether it silently degraded months ago.

Where regulatory readiness asks ‘are we compliant?’ — evaluation readiness asks ‘are we actually checking?’. The answer is most often no.

THRIVE™ Evaluation assessment maps your capacity to commission AI against local thresholds, monitor performance continuously, detect drift, manage incidents, audit independently, and decommission when warranted — closing the loop between procurement decisions and clinical outcomes.

What we assess

Core capabilities

Acceptance & Commissioning Testing

MOVED

Structured execution of formal validation against local clinical requirements before authorising clinical use.

IAEAFDA

QA Programme Readiness

MOVED

Capacity to design and sustain quality control programmes including routine QC, case-specific QA, ad-hoc testing, and workflow audits.

IAEAFDA

Continuous Monitoring Readiness

MOVED

Operational capacity for ongoing real-world performance monitoring, dataset shift detection, and model drift assessment.

IAEAFDAWHO

Override & Contingency Planning

MOVED

Defined processes for clinicians to flag and override AI outputs, combined with system-level contingency plans for AI downtime.

IAEAFDAWHO

Incident Management

MOVED

Defined processes for detecting, classifying, reporting, and resolving AI-related adverse events.

IAEAFDAWHOREADI

Decommissioning Planning

MOVED

End-of-life protocols covering workflow identification, alternative solution selection, security revision, and continuity of care.

IAEA

Real-World Performance Evaluation

NEW

Institutional capability to evaluate deployed AI against actual patient outcomes and feed findings back into procurement and configuration decisions.

FDAWHOREADI

Independent Audit & Internal Validation

NEW

Capability to audit AI performance independently of the vendor and the deploying team.

FDAWHO
Platform integration

How Evaluation connects

THRIVETHRIVE
E ↔ T

Evaluation readiness operationalises what technical readiness demands. T says ‘require local validation’. E determines whether you can actually execute it.

E ↔ R

Post-market surveillance obligations (R) are regulatory requirements. Continuous monitoring capability (E) is how you meet them.

E ↔ I

Monitoring, drift detection, and incident logging all require infrastructure (I) — pipeline instrumentation, logging architecture, and alert systems.

Evidence base

What the literature says

Health-care workers and health systems must have detailed information on the contexts in which such systems can function safely and effectively, the conditions necessary to ensure reliable, appropriate use, and the mechanisms for continuous auditing and assessment of system performance.

WHO, Ethics & Governance of AI for Health (2021)

Deployed models have the capability to be monitored in ‘real world’ use with a focus on maintained or improved safety and performance.

FDA, Good Machine Learning Practice (2021)

It addresses the entire process, from the initial assessment of needs, through selection, commissioning, ongoing management and eventual decommissioning.

IAEA PC9134 (2025)
FAQs

Common questions

Equipment QA tests static performance against fixed specifications. AI QA must test dynamic performance against shifting data distributions, evolving clinical workflows, and model behaviour that changes with updates. The testing paradigm is fundamentally different — you need continuous monitoring, not periodic spot-checks.

Drift means the AI's real-world performance is silently degrading because the data it's processing has changed from the data it was trained on — different patient demographics, different scanner models, different clinical protocols. Without monitoring, drift is invisible until a clinician notices an unusual pattern or a patient is harmed.

Every AI system eventually needs to be retired — due to regulatory changes, better alternatives, vendor end-of-support, or performance degradation. Decommissioning planning ensures clinical workflows don't collapse when that happens. Most organisations have no plan for what happens when they turn an AI system off.

Regulatory surveillance (R) is the obligation. Evaluation readiness (E) is the capability. You can be obligated to monitor without having the infrastructure, processes, or expertise to actually do it. THRIVE™ assesses both.

Ready to assess your Evaluation readiness?

Get started